Table 3.
Dosimetry comparison of [18F]-JK-PSMA-7 with other 18F-labled PSMA tracers
| Organ | [18F]-JK-PSMA-7 This work |
[18F]-PSMA-1007 Giesel et al. [10] |
[18F]-DCFPyL Szabo et al. [7] |
[18F]-DCFBC Cho et al. [6] |
|---|---|---|---|---|
| Mean absorbed dose [mGy/MBq] | ||||
| Number of patients | 10 | 3 | 4 | 5 |
| Used dosimetry software |
QDOSE, ABX-CRO, Germany |
QDOSE, ABX-CRO, Germany |
MIM Software, Cleveland, Ohio |
ANALYZE, BIR, Mayo Clinic |
| Kidneys |
1.76E−01 (6.52E−02 SD) |
1.70E−01 (3.09E−02 SD) |
9.45E−02 (n.a.) |
2.84E−02 (3.81-03 SD) |
| Lungs |
1.10E−02 (2.16E−03 SD) |
1.11E−02 (2.60E−04 SD) |
1.08E−02 (n.a.) |
2.45E−02 (2.99-03 SD) |
| Liver |
7.61E−02 (1.83E−02 SD) |
6.02E−02 (6.24E−04 SD) |
3.80E−02 (n.a.) |
2.46E−02 (4.16-03 SD) |
| Spleen |
1.89E−02 (8.28E−03 SD) |
7.39E−02 (2.96E−02 SD) |
1.85E−02 (n.a.) |
1.72E−02 (1.05E−03 SD) |
| Salivary glands |
4.68E−02 (1.50E−02 SD) |
9.00E−02 (n.a.) |
2.68E−02 (n.a.) |
n.a. |
| Effective dose |
1.09E−02 (2.37E−03 SD) |
2.20E−02 (2.08E−04 SD) |
1.39E−02 (n.a.) |
1.99E−02 (1.34E−03 SD) |
| Mean residence time [MBq·h/MBq] | ||||
| Kidneys |
2.26E−01 (7.83E−02 SD) |
2.64E−01 (5.03E−03 SD) |
2.17E−01 (n.a.) |
3.50E−02 (5.84E−03 SD) |
| Lungs |
4.39E−02 (7.16E−03 SD) |
n.a. |
3.70E−02 (n.a.) |
1.09E–01 (1.87E−02 SD) |
| Liver |
5.70E−01 (1.31E −01 SD) |
4.42E−01 (2.87E−02 SD) |
2.60E−01 (n.a.) |
1.59E−01 (3.29E−02 SD) |
| Spleen |
2.32E−02 (7.09E−03) |
6.29E−02 (2.89E−02 SD) |
2.07E−02 (n.a.) |
1.01E−02 (8.92E−04 SD) |
| Salivary glands |
1.75E−02 (2.68E−03 SD) |
1.37E−02 (3.64E−03 SD) |
6.95E−03 (n.a.) |
n.a. |
| Whole-body |
1.93E+00 (1.48E−01 SD) |
2.64E+00 (0.00 SD)* |
1.96E+00 (n.a.) |
2.37E+00 (9.09E−02 SD) |
n.a. not available, SD standard deviation
*The residence time for the whole-body was the same for all three patients [10]